| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $44,273,958 | 4 | 100 |
| Mastrocola Lauren | Principal Accounting Officer | 0 | $0 | 1 | $2.61M | $-2.61M |
| DeSimone Jill | director | 0 | $0 | 1 | $3.61M | $-3.61M |
| Nemiroff Alex | General Counsel and Secretary | 0 | $0 | 1 | $4.85M | $-4.85M |
| Adage Capital Management, L.P. | 10 percent owner | 0 | $0 | 1 | $33.2M | $-33.2M |
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Over the last 12 months, insiders at Praxis Precision Medicines, Inc. have bought $0 and sold $44.27M worth of Praxis Precision Medicines, Inc. stock.
On average, over the past 5 years, insiders at Praxis Precision Medicines, Inc. have bought $91,955 and sold $17.75M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,500 shares for transaction amount of $25,375 was made by DeSimone Jill (director) on 2023‑10‑05.
| 2026-06-24 | Sale | DeSimone Jill | director | 11,600 0.0559% | $311.32 | $3.61M | +7.83% | |
| 2025-11-20 | Sale | Nemiroff Alex | General Counsel and Secretary | 25,130 0.1399% | $193.09 | $4.85M | +92.66% | |
| 2025-11-20 | Sale | Mastrocola Lauren | Principal Accounting Officer | 13,600 0.0753% | $192.08 | $2.61M | +92.66% | |
| 2025-10-16 | Sale | Adage Capital Management, L.P. | 10 percent owner | 313,910 0.9695% | $105.76 | $33.2M | +90.92% | |
| 2024-11-14 | Sale | Nemiroff Alex | General Counsel and Secretary | 8,239.33 0.0451% | $80.20 | $660,827 | -36.07% | |
| 2024-11-14 | Sale | Mastrocola Lauren | Principal Accounting Officer | 5,188.34 0.029% | $81.78 | $424,318 | -36.07% | |
| 2023-10-05 | DeSimone Jill | director | 14,500 0.0118% | $1.75 | $25,375 | +82.67% | ||
| 2023-06-27 | Souza Marcio | Chief Executive Officer | 10,000 0.0186% | $1.06 | $10,587 | +52.34% | ||
| 2023-03-24 | MITCHELL DEAN J | director | 50,000 0.0964% | $0.84 | $41,815 | +43.72% | ||
| 2023-03-24 | Kelly Timothy Edwin | Chief Financial Officer | 8,000 0.0161% | $0.87 | $6,998 | +43.72% | ||
| 2023-03-23 | Souza Marcio | Chief Executive Officer | 70,001.75 0.1332% | $0.86 | $60,366 | +37.08% | ||
| 2022-06-16 | Mastrocola Lauren | Principal Accounting Officer | 3,000 0.0065% | $1.93 | $5,775 | +14.95% | ||
| 2022-06-13 | Nemiroff Alex | General Counsel and Secretary | 7,500 0.0147% | $1.63 | $12,225 | +22.53% | ||
| 2022-06-09 | Kelly Timothy Edwin | Chief Financial Officer | 10,000 0.0221% | $1.76 | $17,650 | +27.43% | ||
| 2022-06-08 | Souza Marcio | Chief Executive Officer | 27,000 0.0609% | $1.85 | $49,888 | +23.89% | ||
| 2022-06-08 | MITCHELL DEAN J | 25,000 0.0551% | $1.81 | $45,188 | +23.89% | |||
| 2021-10-06 | Sale | BSOF Parallel Master Fund L.P. | 10 percent owner | 400,000 0.8% | $17.50 | $7M | -45.09% | |
| 2021-10-05 | Sale | BSOF Parallel Master Fund L.P. | 10 percent owner | 23,946 0.0534% | $19.15 | $458,566 | -43.95% | |
| 2021-10-01 | Sale | BSOF Parallel Master Fund L.P. | 10 percent owner | 22,600 0.0498% | $19.13 | $432,338 | -43.44% | |
| 2021-08-31 | Kelly Timothy Edwin | Chief Financial Officer | 3,905 0.0086% | $19.48 | $76,069 | -35.35% |
| Adage Capital Management, L.P. | 10 percent owner | 2060175 7.3898% | $711.38M | 0 | 1 | |
| Nemiroff Alex | General Counsel and Secretary | 20832 0.0747% | $7.19M | 1 | 2 | +22.53% |
| Mastrocola Lauren | Principal Accounting Officer | 10442 0.0375% | $3.61M | 1 | 2 | +14.95% |
| DeSimone Jill | director | 2337 0.0084% | $806,966.10 | 1 | 1 | +82.67% |
| Vitorovic Stefan | director | 2939329 10.5432% | $1.01B | 1 | 0 | +1.23% |
| MITCHELL DEAN J | director | 75000 0.269% | $25.9M | 2 | 0 | +33.8% |
| Kelly Timothy Edwin | Chief Financial Officer | 46416 0.1665% | $16.03M | 3 | 0 | +35.57% |
| Souza Marcio | Chief Executive Officer | 45002 0.1614% | $15.54M | 5 | 0 | +23.53% |
| BSOF Parallel Master Fund L.P. | 10 percent owner | 0 0% | $0 | 0 | 10 |
$159,914,414 | 243 | 18.52% | $12.51B | |
$273,531,368 | 93 | 38.24% | $12.63B | |
$2,765,836 | 72 | 20.00% | $12.45B | |
$108,876,545 | 67 | 72.81% | $12.74B | |
$477,065,869 | 34 | 82.05% | $8B | |
$1,801,511 | 23 | 18.58% | $11.64B | |
$11,859,102 | 17 | 18.62% | $9.22B | |
$1,479,484 | 17 | 50.46% | $10.84B | |
$627,701,115 | 15 | 145.68% | $13.99B | |
$118,094,211 | 15 | 38.32% | $9.49B | |
Praxis Precision Medicines, Inc. (PRAX) | $9,976,473 | 12 | 29.52% | $9.63B |
$762,720 | 11 | 52.96% | $9.31B | |
$35,908,794 | 10 | 126.31% | $9.33B | |
$11,898,979 | 10 | 54.58% | $10.26B | |
$948,235 | 8 | 15.54% | $11.31B | |
$55,713,031 | 8 | -0.36% | $8.44B | |
$2,246,813 | 6 | 70.15% | $8.37B | |
$41,376,000 | 4 | -12.07% | $8.59B | |
$50,990,767 | 2 | 19.79% | $8.36B |
| Increased Positions | 198 | +154.69% | 10M | +39.97% |
| Decreased Positions | 61 | -47.66% | 5M | -20.52% |
| New Positions | 113 | New | 4M | New |
| Sold Out Positions | 16 | Sold Out | 531,913 | Sold Out |
| Total Postitions | 265 | +107.03% | 29M | +19.45% |
| Janus Henderson Group Plc | $791,569.00 | 11.06% | 2.76M | +230,454 | +9.1% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $679,938.00 | 9.5% | 2.37M | +399,500 | +20.23% | 2025-09-30 |
| Blackrock, Inc. | $515,829.00 | 7.2% | 1.8M | +210,952 | +13.27% | 2025-09-30 |
| Perceptive Advisors Llc | $448,088.00 | 6.26% | 1.56M | +811,633 | +107.8% | 2025-09-30 |
| Point72 Asset Management, L.P. | $428,450.00 | 5.98% | 1.5M | +541,911 | +56.8% | 2025-09-30 |
| Vanguard Group Inc | $362,951.00 | 5.07% | 1.27M | +51,642 | +4.25% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $287,400.00 | 4.01% | 1M | -469,585 | -31.88% | 2025-09-30 |
| Cormorant Asset Management, Lp | $286,400.00 | 4% | 1M | -625,000 | -38.46% | 2025-09-30 |
| State Street Corp | $259,796.00 | 3.63% | 907,108 | +209,015 | +29.94% | 2025-09-30 |
| Soleus Capital Management, L.P. | $246,065.00 | 3.44% | 859,166 | -107,574 | -11.13% | 2025-09-30 |